Table 2.
Management according to initial diagnosis, age, BMI and treatment duration
| Patient ID | Diagnosis | Age at diagnosis (years) | BMI (kg/m2) | Therapy (mg) | Treatment duration (months) | Follow-up time (months) | Outcome after first treatment | Outcome after last treatment |
|---|---|---|---|---|---|---|---|---|
| 1 | G2EC | 35.9 | 42.8 | Dydrogesteron 10 | 3 | 5 | SD | / |
| 2 | G1EC | 30.7 | 47.9 | MA 160 | 3 + 3 + 3 + 3 | 33 | PR | SD |
| 3 | G1EC | 37.0 | 21.6 | MPA 500 | 3 + 3 | 18 | CR | PR |
| 4 | G1EC | 30.4 | 38.6 | MPA 500 | 3 | 5 | SD | / |
| 5 | G1EC | 31.4 | 42.7 | MPA 500 | 6 + 4 | 40 | PR | CR |
| 6 | G1EC | 30.2 | 40.8 | MPA 500 | 3 | 10 | CR | / |
| 7 | G1EC | 32.9 | 26.7 | MA 160 | 3 | 5 | SD | / |
| 8 | G1EC | 35.6 | 32.2 | MA 320 | 3 | 6 | PR | / |
| 9 | G1EC | 36.6 | 26.9 | MPA 500 | 3 | 4 | CR | / |
| 10 | G1EC | 47.9 | 33.5 | MPA 500 | 1.5 | 6 | PR | / |
| 11 | G1EC | 30.6 | 28.5 | MA 160 | 2.5 | 40 | CR | / |
| 12 | CAH | 31.6 | 36.7 | MPA 500 | 3 | 7 | CR | / |
| 13 | CAH | 30.1 | 23.4 | MA 160 | 4 + 3 | 46 | CR | CR |
| 14 | CAH | 37.4 | 22.2 | MPA 500 | 3 | 11 | CR | / |
G2EC Endometrial cancer grade 2, G1EC Endometrial cancer grade 1, CAH Complex atypical hyperplasia, SD stable disease, PR partial remission, CR complete remission